{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:27:23Z","timestamp":1790083643241,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014735","name":"Royal College of Physicians and Surgeons of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003151","name":"Fonds de recherche du Quebec Nature et technologies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ajt.2024.05.019","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:18:44Z","timestamp":1718219924000},"page":"1558-1566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-7875","authenticated-orcid":false,"given":"Lorne","family":"Schweitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4446-6385","authenticated-orcid":false,"given":"Pawel","family":"Muranski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ajt.2024.05.019_bib1","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"16","key":"10.1016\/j.ajt.2024.05.019_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ajt.2024.05.019_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MOH.0000000000000461","article-title":"Restoring antiviral immunity with adoptive transfer of ex-vivo generated T cells","volume":"25","author":"Migliori","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"10.1016\/j.ajt.2024.05.019_bib5","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib6","first-page":"199","article-title":"Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation","volume":"31","author":"Feuchtinger","year":"2008","journal-title":"J\u00a0Immunother"},{"issue":"1","key":"10.1016\/j.ajt.2024.05.019_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"8941","key":"10.1016\/j.ajt.2024.05.019_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajt.2024.05.019_bib9","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein-Barr virus (EBV)\u2013specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ajt.2024.05.019_bib10","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ajt.2024.05.019_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2023.01.027","article-title":"Third-Party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplantation in children and young adults","volume":"29","author":"Galletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.ajt.2024.05.019_bib12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2024.05.019_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/tan.15419","article-title":"Development and characterization of a cell donor registry for virus-specific T cell manufacture in a blood bank","volume":"103","author":"Rudilla","year":"2024","journal-title":"HLA"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13133","article-title":"Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children","volume":"22","author":"Chiou","year":"2018","journal-title":"Pediatr Transplant"},{"issue":"1 Suppl","key":"10.1016\/j.ajt.2024.05.019_bib15","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2010.11.008","article-title":"Viral infections in immunocompromised patients","volume":"17","author":"Englund","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.ajt.2024.05.019_bib16","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.ajt.2024.05.019_bib17","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ajt.2024.05.019_bib18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ajt.2024.05.019_bib19","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1365-2141.2002.03683.x","article-title":"Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma","volume":"118","author":"Sun","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ajt.2024.05.019_bib20","first-page":"170","article-title":"T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I\/II feasibility and safety study","volume":"37","author":"Gallot","year":"2014","journal-title":"J\u00a0Immunother"},{"issue":"12","key":"10.1016\/j.ajt.2024.05.019_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.ajt.2024.05.019_bib23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ajt.2024.05.019_bib24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.ajt.2024.05.019_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ajt.2024.05.019_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: a pre-COVID-19 survey from the Working Group of the European Society for Organ Transplantation","volume":"35","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.ajt.2024.05.019_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a Phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/cid\/ciad575","article-title":"Immune monitoring-guided versus fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients: a multicenter, randomized clinical trial","volume":"78","author":"Manuel","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.ajt.2024.05.019_bib29","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1600-6143.2009.02672.x","article-title":"Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy","volume":"9","author":"Brestrich","year":"2009","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2024.05.019_bib30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.healun.2015.12.031","article-title":"Novel autologous T-cell therapy for drug-resistant cytomegalovirus disease after lung transplantation","volume":"35","author":"Pierucci","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2024.05.019_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunology"},{"issue":"3","key":"10.1016\/j.ajt.2024.05.019_bib32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ajt.13023","article-title":"Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient","volume":"15","author":"Macesic","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2024.05.019_bib33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/microorganisms9040684","article-title":"Successful use of heterologous CMV-reactive T lymphocyte to treat severe refractory cytomegalovirus (CMV) infection in a liver transplanted patient: correlation of the host antiviral immune reconstitution with CMV viral load and CMV miRNome","volume":"9","author":"Miele","year":"2021","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.ajt.2024.05.019_bib34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ajt.2024.05.019_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14179","article-title":"Viral specific T cell therapy in kidney transplant recipients \u2013 a single-center experience","volume":"25","author":"Anand","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.ajt.2024.05.019_bib36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41598-023-27850-7","article-title":"Seroprevalence of polyomaviruses BK and JC in Finnish women and their spouses followed-up for three years","volume":"13","author":"Laine","year":"2023","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ajt.2024.05.019_bib37","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jcyt.2017.08.011","article-title":"T\u00a0cell therapies for human polyomavirus diseases","volume":"19","author":"Davies","year":"2017","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.ajt.2024.05.019_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13528","article-title":"BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Hirsch","year":"2019","journal-title":"Clin Transplant"},{"issue":"22","key":"10.1016\/j.ajt.2024.05.019_bib39","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv","volume":"4","author":"Nelson","year":"2020"},{"issue":"5","key":"10.1016\/j.ajt.2024.05.019_bib40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1681\/ASN.0000000000000329","article-title":"Posoleucel in kidney transplant recipients with BK viremia: multicenter, randomized, double-blind, placebo-controlled Phase 2 trial","volume":"35","author":"Chandraker","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2024.05.019_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ana.26020","article-title":"Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy","volume":"89","author":"Berzero","year":"2021","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.ajt.2024.05.019_bib42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.healun.2022.04.001","article-title":"Successful JC virus-targeted T-cell therapy for progressive multifocal leukoencephalopathy in a lung transplant recipient","volume":"41","author":"Peghin","year":"2022","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2024.05.019_bib43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","article-title":"BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study","volume":"20","author":"Cortese","year":"2021","journal-title":"Lancet Neurol"},{"issue":"15","key":"10.1016\/j.ajt.2024.05.019_bib44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus\u2013specific T cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N\u00a0Engl J Med."},{"issue":"4","key":"10.1016\/j.ajt.2024.05.019_bib45","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001020","article-title":"Allogeneic BK virus-specific T-cell treatment in 2 patients with progressive multifocal leukoencephalopathy","volume":"8","author":"Hopfner","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib46","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.jtct.2021.11.005","article-title":"Off-the-shelf third-party virus-specific T cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplantation recipients","volume":"28","author":"Rubinstein","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.ajt.2024.05.019_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13527","article-title":"Adenovirus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Florescu","year":"2019","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ajt.2024.05.019_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"Suppl 1","key":"10.1016\/j.ajt.2024.05.019_bib50","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1182\/blood-2023-189708","article-title":"ALVR106, an off-the-shelf, multivirus-specific T-cell therapy, for the treatment of respiratory viral infections: results from a phase 1, first-in-human, dose-ranging trial","volume":"142","author":"Nikiforow","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ajt.2024.05.019_bib51","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/ajt.16927","article-title":"ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: case report","volume":"22","author":"Martits-Chalangari","year":"2022","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2024.05.019_bib52","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s11357-023-00858-7","article-title":"Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review","volume":"46","author":"Gopcsa","year":"2024","journal-title":"GeroScience"},{"issue":"22","key":"10.1016\/j.ajt.2024.05.019_bib53","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ajt.2024.05.019_bib54","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/mt.2014.48","article-title":"Systemic inflammatory response syndrome after administration of unmodified T lymphocytes","volume":"22","author":"Papadopoulou","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajt.2024.05.019_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.801281","article-title":"Case report: fatal complications of BK virus-hemorrhagic cystitis and severe cytokine release syndrome following BK virus-specific T-cells","volume":"12","author":"Holland","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ajt.2024.05.019_bib56","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ajt.2024.05.019_bib57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-Edited tacrolimus-resistant antiviral T cells for advanced adoptive immunotherapy in transplant recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol Ther"},{"issue":"14","key":"10.1016\/j.ajt.2024.05.019_bib58","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/bloodadvances.2020001977","article-title":"Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613524003472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613524003472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T02:25:26Z","timestamp":1756693526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613524003472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1600613524003472"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2024.05.019","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2024.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}